This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments - Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biom
Global Uro-Gynecological Surgical Devices IndustryReportLinker.com
This report analyzes the worldwide markets for Uro-Gynecological Surgical Devices in US$ Million by the following segments: Urological Surgical Devices (Sling & Suspension Devices, & Other Urological Devices), and Gynecological Surgical Devices (Endometrial Ablation Devices, Endoscopes, Hysteroscope Systems, Fluid Management Systems, & Other Gynecological Devices). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia'Pacific, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 66 companies including many key and niche players such as Gyrus ACMI Corporation, American Medical Systems Holdings Incorporated, Boston Scientific Corporation, C. R. Bard, Inc., Cook Urological Inc., CooperSurgical, Inc., Hologic Inc., Ethicon, Inc., Cytyc Corporation, Cytyc Surgical Products, Ethicon Inc., Karl Storz GmbH & Co. KG, MDMI Technologies, Inc., Medtronic, Inc., Olympus America Inc., Olympus Surgical & Industrial America, Inc., Richard Wolf GmbH, and Stryker Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Russian Federation Anesthesia and Respiratory Devices Market Outlook to 2018 ...ReportsnReports
This report provides an in-depth analysis of the Russian anesthesia and respiratory devices market from 2004-2018. It covers market segmentation and revenue for various device categories, including respiratory devices, anesthesia machines, sleep apnea diagnostic systems, and more. Major players in the Russian market are also profiled. The 279-page report is based on proprietary databases and includes historical data as well as forecasts through 2018. It is intended to help companies develop business and market strategies for opportunities in the Russian anesthesia and respiratory devices market.
Russian Federation Patient Monitoring Market Outlook to 2018 - Fetal Monitors...ReportsnReports
This report provides an in-depth analysis of the Russian patient monitoring market from 2004-2018. It examines market size and trends for 7 categories of patient monitoring devices, including multiparameter monitoring, non-invasive blood pressure monitors, and neonatal monitors. The 168-page report provides historical and forecasted data on revenue, volume, and price for each segment. It also includes company market share analysis and profiles of major players in the Russian patient monitoring space. Purchasing the report gives access to detailed industry data that can be used to inform business strategies around market entry and expansion in Russia.
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade.
Global Psoriasis Pipeline Drugs Market Assessment – Forecast to 2023AzothAnalytics
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
Global Angiongenesis Inhibitors and Stimulators IndustryReportLinker.com
This document summarizes a report on the global angiogenesis inhibitors and stimulators industry. It provides an overview of key market trends such as the cancer market being the main target for anti-angiogenesis drugs and Avastin continuing to record robust growth. It also outlines major product approvals and launches, for example Pfizer obtaining European approval for SUTENT to treat pancreatic neuroendocrine tumors. The report analyzes markets for angiogenesis inhibitors and stimulators by region and forecasts revenues from 2007 to 2015.
This report provides a detailed analysis of the global catheter market, including different types of catheters used for cardiovascular, urological, intravenous, and other applications. It discusses key disease conditions driving catheter usage, trends in the overall medical device industry, and projections for catheter sales by region through 2018. The report also profiles major companies in the catheter market and their product portfolios.
Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Co...Renub Research
Renub Research (http://www.renub.com/report/personalized-medicine-diagnostics-flow-cytometry-sepsis-immunos-routine-coagulation-psychiatric-disorders-tumor-markers-molecular-blood-typing-and-other-testing-116) has announced the addition of the "Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)" report to its offering
Global Uro-Gynecological Surgical Devices IndustryReportLinker.com
This report analyzes the worldwide markets for Uro-Gynecological Surgical Devices in US$ Million by the following segments: Urological Surgical Devices (Sling & Suspension Devices, & Other Urological Devices), and Gynecological Surgical Devices (Endometrial Ablation Devices, Endoscopes, Hysteroscope Systems, Fluid Management Systems, & Other Gynecological Devices). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia'Pacific, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 66 companies including many key and niche players such as Gyrus ACMI Corporation, American Medical Systems Holdings Incorporated, Boston Scientific Corporation, C. R. Bard, Inc., Cook Urological Inc., CooperSurgical, Inc., Hologic Inc., Ethicon, Inc., Cytyc Corporation, Cytyc Surgical Products, Ethicon Inc., Karl Storz GmbH & Co. KG, MDMI Technologies, Inc., Medtronic, Inc., Olympus America Inc., Olympus Surgical & Industrial America, Inc., Richard Wolf GmbH, and Stryker Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Russian Federation Anesthesia and Respiratory Devices Market Outlook to 2018 ...ReportsnReports
This report provides an in-depth analysis of the Russian anesthesia and respiratory devices market from 2004-2018. It covers market segmentation and revenue for various device categories, including respiratory devices, anesthesia machines, sleep apnea diagnostic systems, and more. Major players in the Russian market are also profiled. The 279-page report is based on proprietary databases and includes historical data as well as forecasts through 2018. It is intended to help companies develop business and market strategies for opportunities in the Russian anesthesia and respiratory devices market.
Russian Federation Patient Monitoring Market Outlook to 2018 - Fetal Monitors...ReportsnReports
This report provides an in-depth analysis of the Russian patient monitoring market from 2004-2018. It examines market size and trends for 7 categories of patient monitoring devices, including multiparameter monitoring, non-invasive blood pressure monitors, and neonatal monitors. The 168-page report provides historical and forecasted data on revenue, volume, and price for each segment. It also includes company market share analysis and profiles of major players in the Russian patient monitoring space. Purchasing the report gives access to detailed industry data that can be used to inform business strategies around market entry and expansion in Russia.
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade.
Global Psoriasis Pipeline Drugs Market Assessment – Forecast to 2023AzothAnalytics
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Psoriasis Pipeline Drugs Market by assessing the potential of the six drugs that will be launched in the near future. Also, the report assesses the results of various clinical trials undertaken for each of the six drugs, the product profile, description and regulatory phase of each of the six drugs. Also, 7Ps Analysis (Patent, Phase, Pathway, Patient, Physician, Payer, Partner) has been done for each of the six drugs to present the current perspective.
Global Angiongenesis Inhibitors and Stimulators IndustryReportLinker.com
This document summarizes a report on the global angiogenesis inhibitors and stimulators industry. It provides an overview of key market trends such as the cancer market being the main target for anti-angiogenesis drugs and Avastin continuing to record robust growth. It also outlines major product approvals and launches, for example Pfizer obtaining European approval for SUTENT to treat pancreatic neuroendocrine tumors. The report analyzes markets for angiogenesis inhibitors and stimulators by region and forecasts revenues from 2007 to 2015.
This report provides a detailed analysis of the global catheter market, including different types of catheters used for cardiovascular, urological, intravenous, and other applications. It discusses key disease conditions driving catheter usage, trends in the overall medical device industry, and projections for catheter sales by region through 2018. The report also profiles major companies in the catheter market and their product portfolios.
Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Co...Renub Research
Renub Research (http://www.renub.com/report/personalized-medicine-diagnostics-flow-cytometry-sepsis-immunos-routine-coagulation-psychiatric-disorders-tumor-markers-molecular-blood-typing-and-other-testing-116) has announced the addition of the "Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing)" report to its offering
Cytori Corporate Overview provides an overview of Cytori Therapeutics, Inc., a company that develops cell therapy technology. The summary includes:
1) Cytori has a transformative cell therapy platform that is regulated as a device and uses a business model of single-use consumables.
2) The technology has clinical experience in thousands of patients and strong intellectual property protection.
3) Near-term value drivers include milestones from a U.S. government contract, upcoming cardiovascular trial data, and international approvals and revenue growth.
2012 Global and China cardiac stent industry depth research reportReportsnReports
This 234-page report provides an in-depth analysis of the global and Chinese cardiac stent industry from 2009-2013. It covers topics such as market size, production capacity, market share, pricing, costs, and competitive landscape of the top 16 global and 6 Chinese companies. It also analyzes industry trends, opportunities, challenges, and provides strategic recommendations. The report aims to support customers in competitive analysis, development planning, and investment decision making within the cardiac stent industry.
This corporate presentation summarizes clinical data from YM BioSciences' Phase I/II study of CYT387, a JAK1/JAK2 inhibitor being developed for the treatment of myelofibrosis. Key findings from the updated data presented at ASH 2011 include:
1) Over half of previously transfusion-dependent patients became transfusion-independent within 12 weeks at doses of 150-300mg QD.
2) Spleen responses occurred in approximately 30% of patients across doses based on IWG-MRT criteria.
3) Constitutional symptoms such as night sweats, pruritis and bone pain showed complete resolution or marked improvement in the majority of patients.
The global interventional cardiology and peripheral vascular devices market was valued at $8.7 billion in 2011 and is expected to grow to $12.7 billion by 2016. The market consists of devices used in coronary and peripheral endovascular procedures. Major drivers of growth include increasing demand for minimally invasive treatments and rising rates of coronary and peripheral artery diseases. North America currently dominates the market but Asia is growing the fastest.
Diagnostic electrophysiology (ep) catheters global trends, estimates and fo...Research Hub
The document summarizes a report on the global diagnostic electrophysiology catheters market. Some key points:
- The global market is projected to reach $3.5 billion by 2016, with North America and Europe currently accounting for over 60% of the market. Asia-Pacific is the fastest growing region.
- Conventional EP diagnostic catheters have over 40% of the global market share currently.
- The report analyzes the market size, trends, growth rates, investment opportunities, and major players in the diagnostic electrophysiology catheters industry from 2012-2018. It provides a detailed segmentation of the market by region and product type.
johnson & johnson Q4 2008 Investor Relations Business Overview finance4
This document contains a safe harbor statement for Johnson & Johnson noting that the press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. It also provides a list of specific risks and uncertainties the company faces and directs readers to further information in the company's annual report. The statement does not guarantee the company's financial performance but aims to fairly advise investors and analysts of known risks.
The document summarizes coverage from Meddevicetracker on the recent EuroPCR event, an annual cardiovascular conference. It provides instructions on how to search Meddevicetracker's database to find information on events that occurred at EuroPCR 2016, including an example of results found for a trial on the Lotus heart valve. The database also allows viewing analyses of medical devices and technologies presented, such as a bioresorbable vascular scaffold called Fantom. Users can filter the competitive landscape by product type, with an example given focusing on drug-eluting stents.
Poland Patient Monitoring Investment Opportunities, Analysis and Forecasts to...ReportsnReports
The document is a 138-page report from Global Markets Direct analyzing investment opportunities in the patient monitoring market in Poland from 2012 to 2018. It provides market size data for seven categories of patient monitoring from 2004 to 2011, and forecasts from 2011 to 2018. It also provides company share data for 2010-2011. The report is available for purchase for $2,500 and contains detailed data tables, analysis, and profiles of major market players.
Cytori Therapeutics is developing adipose-derived regenerative cell therapies using a point-of-care device platform. The platform allows for autologous cell therapies to be prepared at the bedside from a patient's own fat tissue. Clinical trials show the cells are safe and may provide benefits in cardiac and soft tissue applications. Near-term value drivers include government contract milestones and cardiovascular trial data. The business model involves selling single-use consumables for each procedure at price points around $2,000-$12,000, depending on the indication.
This document provides a summary of the global patient monitoring market from 2012-2020. It discusses key market segments such as devices (cardiac, prenatal, etc.), end-users (medical centers, home users), and regions (North America, Europe, Asia Pacific). The global market is expected to reach $XX million by 2020, growing at 5.2% annually. North America currently dominates the market but Asia Pacific is expected to see the fastest growth. Cardiac monitoring accounts for the largest segment currently but remote monitoring is growing the fastest. The report provides market size data and forecasts for each segment.
Ethocle Reports has published its latest Market Research Report on CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – US. Develop business strategies by understanding the trends shaping and driving the US healthcare market. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – US. Develop business strategies by understanding the trends shaping and driving the US healthcare market. Browse market data tables and figures.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) Visit us: http://azothanalytics.com/report/healthcare-pharma/global-nuclear-medicine-market-analysis-by-product-type-diagnostic-therapeutic-by-diagnostic-nuclear-medicine-type-by-therapeutic-nuclear-medicine-type-by-indication-by-region-by-country-2019-edition-opportunities-and-forecast-2013-2023-r28197
Over-the-Counter Diagnostic Products World MarketsReportsnReports
This document provides a detailed summary and analysis of the over-the-counter (OTC) diagnostic products and home healthcare markets. It examines diagnostic devices and tests that can be used directly by patients at home to diagnose and monitor health conditions. The report analyzes market size, growth trends, key players, and opportunities in major product segments like glucose monitoring, pregnancy testing, infectious disease testing, drugs of abuse screening, and more. It also discusses regulatory issues, reimbursement trends, technology developments, and challenges and opportunities in the OTC diagnostic industry.
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market AnalysisInsights10
Neuromyelitis Optica Spectrum Disorder (NMOSD) is previously known as device syndrome is a rare, lifelong, and inflammatory autoimmune disease of the central nervous system that damages the optic nerve as well as spinal cord. The characteristics signs and symptoms of Neuromyelitis Optica Spectrum Disorder (NMOSD) is optic nerve inflammation which eventually leads to the loss of clear vision. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market is expected to gain market growth in the forecast period of 2019 to 2028. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. The global Neuromyelitis Optica Spectrum Disorder (NMOSD) market is majorly driven by the high incidence of Neuromyelitis Optica Spectrum Disorder (NMOSD) and promising pipeline drugs portfolio. In addition, emergence of drugs used in the prevention of Neuromyelitis Optica Spectrum Disorder (NMOSD) and improvement in healthcare facilities are some of the impacting factors that drives the market growth.
Rise in incidence of neuromyelitis optica spectrum disorder is likely propel the neuromyelitis optica spectrum disorder market. Moreover, increase in research & development by key players is anticipated to drive the market. Several players are investing in development of products for the treatment of neuromyelitis optica spectrum disorder. Thus, key players have a strong pipeline. Furthermore, introduction of new products by key players is anticipated to drive the neuromyelitis optica spectrum disorder market. Emergence of new therapies for acute phase or prevention of neuromyelitis optica spectrum disorder creates lucrative opportunity for the market.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us at info@insights10.com
Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase
Russian Federation Diagnostic Imaging Market Outlook to 2018 - Ultrasound Sys...ReportsnReports
This report provides an in-depth analysis of the diagnostic imaging market in Russia from 2004-2018. It covers market size, segmentation, trends, and company shares across 10 categories, including ultrasound systems, MRI systems, CT systems, x-ray systems, and more. Key data points include revenue, volume, average price for each category and sub-segment. The 228-page report also profiles major industry players and can be purchased for $2,500.
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biom
This report analyzes the worldwide markets for HIV/AIDS Testing in US$ Million by the following product segments: HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Monitoring Tests. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 63 companies including many key and niche players such as Abbott Laboratories Inc., Abbott Molecular Inc., Adaltis S.r.l., Biom
Cytori Corporate Overview provides an overview of Cytori Therapeutics, Inc., a company that develops cell therapy technology. The summary includes:
1) Cytori has a transformative cell therapy platform that is regulated as a device and uses a business model of single-use consumables.
2) The technology has clinical experience in thousands of patients and strong intellectual property protection.
3) Near-term value drivers include milestones from a U.S. government contract, upcoming cardiovascular trial data, and international approvals and revenue growth.
2012 Global and China cardiac stent industry depth research reportReportsnReports
This 234-page report provides an in-depth analysis of the global and Chinese cardiac stent industry from 2009-2013. It covers topics such as market size, production capacity, market share, pricing, costs, and competitive landscape of the top 16 global and 6 Chinese companies. It also analyzes industry trends, opportunities, challenges, and provides strategic recommendations. The report aims to support customers in competitive analysis, development planning, and investment decision making within the cardiac stent industry.
This corporate presentation summarizes clinical data from YM BioSciences' Phase I/II study of CYT387, a JAK1/JAK2 inhibitor being developed for the treatment of myelofibrosis. Key findings from the updated data presented at ASH 2011 include:
1) Over half of previously transfusion-dependent patients became transfusion-independent within 12 weeks at doses of 150-300mg QD.
2) Spleen responses occurred in approximately 30% of patients across doses based on IWG-MRT criteria.
3) Constitutional symptoms such as night sweats, pruritis and bone pain showed complete resolution or marked improvement in the majority of patients.
The global interventional cardiology and peripheral vascular devices market was valued at $8.7 billion in 2011 and is expected to grow to $12.7 billion by 2016. The market consists of devices used in coronary and peripheral endovascular procedures. Major drivers of growth include increasing demand for minimally invasive treatments and rising rates of coronary and peripheral artery diseases. North America currently dominates the market but Asia is growing the fastest.
Diagnostic electrophysiology (ep) catheters global trends, estimates and fo...Research Hub
The document summarizes a report on the global diagnostic electrophysiology catheters market. Some key points:
- The global market is projected to reach $3.5 billion by 2016, with North America and Europe currently accounting for over 60% of the market. Asia-Pacific is the fastest growing region.
- Conventional EP diagnostic catheters have over 40% of the global market share currently.
- The report analyzes the market size, trends, growth rates, investment opportunities, and major players in the diagnostic electrophysiology catheters industry from 2012-2018. It provides a detailed segmentation of the market by region and product type.
johnson & johnson Q4 2008 Investor Relations Business Overview finance4
This document contains a safe harbor statement for Johnson & Johnson noting that the press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. It also provides a list of specific risks and uncertainties the company faces and directs readers to further information in the company's annual report. The statement does not guarantee the company's financial performance but aims to fairly advise investors and analysts of known risks.
The document summarizes coverage from Meddevicetracker on the recent EuroPCR event, an annual cardiovascular conference. It provides instructions on how to search Meddevicetracker's database to find information on events that occurred at EuroPCR 2016, including an example of results found for a trial on the Lotus heart valve. The database also allows viewing analyses of medical devices and technologies presented, such as a bioresorbable vascular scaffold called Fantom. Users can filter the competitive landscape by product type, with an example given focusing on drug-eluting stents.
Poland Patient Monitoring Investment Opportunities, Analysis and Forecasts to...ReportsnReports
The document is a 138-page report from Global Markets Direct analyzing investment opportunities in the patient monitoring market in Poland from 2012 to 2018. It provides market size data for seven categories of patient monitoring from 2004 to 2011, and forecasts from 2011 to 2018. It also provides company share data for 2010-2011. The report is available for purchase for $2,500 and contains detailed data tables, analysis, and profiles of major market players.
Cytori Therapeutics is developing adipose-derived regenerative cell therapies using a point-of-care device platform. The platform allows for autologous cell therapies to be prepared at the bedside from a patient's own fat tissue. Clinical trials show the cells are safe and may provide benefits in cardiac and soft tissue applications. Near-term value drivers include government contract milestones and cardiovascular trial data. The business model involves selling single-use consumables for each procedure at price points around $2,000-$12,000, depending on the indication.
This document provides a summary of the global patient monitoring market from 2012-2020. It discusses key market segments such as devices (cardiac, prenatal, etc.), end-users (medical centers, home users), and regions (North America, Europe, Asia Pacific). The global market is expected to reach $XX million by 2020, growing at 5.2% annually. North America currently dominates the market but Asia Pacific is expected to see the fastest growth. Cardiac monitoring accounts for the largest segment currently but remote monitoring is growing the fastest. The report provides market size data and forecasts for each segment.
Ethocle Reports has published its latest Market Research Report on CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – US. Develop business strategies by understanding the trends shaping and driving the US healthcare market. Browse market data tables and figures.
Ethocle Reports has published its latest Market Research Report on CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – US. Develop business strategies by understanding the trends shaping and driving the US healthcare market. Browse market data tables and figures.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) Visit us: http://azothanalytics.com/report/healthcare-pharma/global-nuclear-medicine-market-analysis-by-product-type-diagnostic-therapeutic-by-diagnostic-nuclear-medicine-type-by-therapeutic-nuclear-medicine-type-by-indication-by-region-by-country-2019-edition-opportunities-and-forecast-2013-2023-r28197
Over-the-Counter Diagnostic Products World MarketsReportsnReports
This document provides a detailed summary and analysis of the over-the-counter (OTC) diagnostic products and home healthcare markets. It examines diagnostic devices and tests that can be used directly by patients at home to diagnose and monitor health conditions. The report analyzes market size, growth trends, key players, and opportunities in major product segments like glucose monitoring, pregnancy testing, infectious disease testing, drugs of abuse screening, and more. It also discusses regulatory issues, reimbursement trends, technology developments, and challenges and opportunities in the OTC diagnostic industry.
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market AnalysisInsights10
Neuromyelitis Optica Spectrum Disorder (NMOSD) is previously known as device syndrome is a rare, lifelong, and inflammatory autoimmune disease of the central nervous system that damages the optic nerve as well as spinal cord. The characteristics signs and symptoms of Neuromyelitis Optica Spectrum Disorder (NMOSD) is optic nerve inflammation which eventually leads to the loss of clear vision. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) market is expected to gain market growth in the forecast period of 2019 to 2028. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market. The global Neuromyelitis Optica Spectrum Disorder (NMOSD) market is majorly driven by the high incidence of Neuromyelitis Optica Spectrum Disorder (NMOSD) and promising pipeline drugs portfolio. In addition, emergence of drugs used in the prevention of Neuromyelitis Optica Spectrum Disorder (NMOSD) and improvement in healthcare facilities are some of the impacting factors that drives the market growth.
Rise in incidence of neuromyelitis optica spectrum disorder is likely propel the neuromyelitis optica spectrum disorder market. Moreover, increase in research & development by key players is anticipated to drive the market. Several players are investing in development of products for the treatment of neuromyelitis optica spectrum disorder. Thus, key players have a strong pipeline. Furthermore, introduction of new products by key players is anticipated to drive the neuromyelitis optica spectrum disorder market. Emergence of new therapies for acute phase or prevention of neuromyelitis optica spectrum disorder creates lucrative opportunity for the market.
Visit https://insights10.com/ for more healthcare industry insights.
Connect with us at info@insights10.com
Nonalcoholic Steatohepatitis (NASH) also known as “silent disease” is a type of fatty liver disease, which mainly affects people with diabetes and obesity. Symptoms of NASH are found among all demographics (from children to adults); however, they are more prevalent in younger people. Corner stage of cirrhosis is a form of NASH that can be reversed with proper medication. Moreover, most of the NASH specific pharmaceutical solution are in clinical trial phase
Russian Federation Diagnostic Imaging Market Outlook to 2018 - Ultrasound Sys...ReportsnReports
This report provides an in-depth analysis of the diagnostic imaging market in Russia from 2004-2018. It covers market size, segmentation, trends, and company shares across 10 categories, including ultrasound systems, MRI systems, CT systems, x-ray systems, and more. Key data points include revenue, volume, average price for each category and sub-segment. The 228-page report also profiles major industry players and can be purchased for $2,500.
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 101 companies including many key and niche players such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biom
This report analyzes the worldwide markets for HIV/AIDS Testing in US$ Million by the following product segments: HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Monitoring Tests. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets.The report profiles 63 companies including many key and niche players such as Abbott Laboratories Inc., Abbott Molecular Inc., Adaltis S.r.l., Biom
Healthcare, Regulatory and Reimbursement Landscape - IsraelReportsnReports
The document provides a 145-page report on Israel's healthcare, regulatory, and reimbursement landscape published in December 2012. It identifies key trends in Israel's growing healthcare market, including a population of 7.8 million in 2011 and total pharmaceutical and medical device markets projected to reach $2.3 billion and $1.9 billion respectively by 2020. The report provides an in-depth analysis of Israel's political, economic, and demographic factors influencing the healthcare system as well as insights into major players, market drivers, regulations, and opportunities in the pharmaceutical and medical device industries.
The document analyzes the global market for contrast agents used in medical imaging modalities like X-ray, CT, ultrasound, MRI, PET, and SPECT. It provides revenue forecasts for contrast agents by modality and region through 2012, as well as market share information for major suppliers. The report also discusses new applications and technological developments that are expanding the role of contrast agents in areas like disease diagnosis, drug development, and medical research.
This report analyzes the worldwide markets for Urological Catheters in Thousand Units and US$ Million by the following product segments: Dialysis Catheters (Hemodialysis, & Peritoneal), and Urinary Catheters (Foley, Intermittent, & External/Condom). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Middle East. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. A seven-year historic analysis is also provided for these markets. The report profiles 58 companies including many key and niche players such as Boston Scientific Corp., C R Bard, Inc., Bard Medical Division, Coloplast A/S, Cook Urological, Inc., Covidien Ltd., Hollister, Inc., and Rochester Medical Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.
This report analyzes the worldwide markets for Imaging Agents in US$ Million by the following product segments - Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 55 companies including many key and niche players such as AMAG Pharmaceuticals Inc., Bayer Schering Pharma AG, Bracco Group, Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, GE Healthcare, Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
This document provides an overview and summary of the global clinical laboratory instrumentation and reagent market. It examines segments from small lab equipment to highly automated large platforms and accessories like reagents. The emphasis is on companies and products actively developing and marketing clinical laboratory analyzers for hospitals, independent labs, doctors offices and clinics. The report focuses on the instrumentation industry market and companion reagent sector in the US, Europe, Asia and rest of world. It pays particular attention to areas showing the greatest growth and most innovation.
This document provides an overview and summary of the global clinical laboratory instrumentation and reagent market. It examines segments from small lab equipment to highly automated large platforms and accessories like reagents. The emphasis is on companies and products actively developing and marketing clinical laboratory analyzers for hospitals, independent labs, doctors offices and clinics. The report focuses on the instrumentation industry market and companion reagent sector in the US, Europe, Asia and rest of world. It pays particular attention to areas showing the greatest growth and most innovation.
Research aarkstore enterprise medical imaging markets Neel Terde
The document summarizes a new market research report from Aarkstore titled "ResearchAarkstore Enterprise Medical Imaging Markets". The report describes the medical imaging market, which includes modalities like X-rays, ultrasound, CT, PET, SPECT, MRI, nuclear medicine, mammography and fluoroscopy. X-rays are the most commonly used, followed by MRI. The report surveys companies involved in medical imaging equipment and supplies, discussing each company's history, products, business analysis and market position. It includes tables, charts and sales forecasts.
Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and TherapeuticsReportLinker.com
THIS REPORT:Provides a comprehensive overview of the global market for epigenomicsDescribes the major epigenomics technologies impacting the market today and emerging opportunities in biomarkers, diagnostics and therapeuticsContains global market forecasts for epigenomics, with trends and forecasts for growth through 2014Offers a focus on particular applications of epigenomics, including research tools, diagnostics, drugs and cloning/tissue engineeringDiscusses industry structure including, mergers and acquisitions, distribution of products, government regulation and industry trendsProfiles the most competitive businesses in the industry.
Minimally invasive medical robotics, imaging & visualization systems & surgic...Ron Ethell
The MIS market is expected to grow at a fast rate with a CAGR of 8.2% and is expected to reach $35.5 billion by 2016. The surgical instruments segment commanded the larger share; i.e. 38.4%, of the global minimally invasive surgical devices market in 2011. This growth has been primarily attributed to the increased usage of these devices and instruments in MIS procedures. Devices such as guiding catheters and guidewires as well as balloons have been widely used in interventional angioplasty and peripheral extremity MIS procedures. Numerous innovations in the technologies of devices such as balloons have added to the growth in the market.
Dr. Michael S. Perry - Afternoon Keynote Presentationmarsinnovation
Michael Perry gave a presentation at the MaRS Innovation Summit in Toronto, Canada on October 28, 2010. He discussed trends in pharmaceutical R&D including rising costs of drug development and declining productivity. He noted significant unmet medical needs in areas like oncology, cardiovascular disease, and diabetes. Perry also talked about how venture capital like Bay City Capital is fueling innovation by translating academic research into potential drugs and funding their development through commercialization. However, industry faces challenges like large patent cliffs and risk aversion. Perry proposed strategies like the Pharma Innovation Fund to help bridge gaps in translating discoveries into treatments.
"The Global In Vitro Diagnostics (IVD) Market is calculated to reach $91.49 billion by 2024, at a CAGR of
6.01% during the forecast period 2019-2024. The rising demand for early and accurate disease diagnosis, increasing adoption of fully-automated instruments and automation in laboratories,
increasing adoption of point-of-care testing, and growing awareness of personalized medicine are the
key factors driving the growth of the market."
Blood Culture Test Market Growth, Demand and Challenges of the Key Industry P...IMARC Group
The global blood culture test market size reached US$ 5.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.9 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.
More Info:- https://www.imarcgroup.com/blood-culture-test-market
The global Peripheral Vascular Devices market is segregated on the basis of Product as EVAR Stent Grafts, Inferior Vena Cava Filters, Hemodynamic Flow Alteration Devices, Angioplasty Balloons, Angioplasty Stents, Catheters, Plaque Modification Devices, and Other Devices.
The document summarizes key happenings and trends from the 2014 AACC annual meeting and clinical lab expo in Chicago. Specifically:
- Point of care and infectious disease testing were highlighted areas with over 20% of exhibitors.
- Emerging "grassroots molecular" point of care systems were showcased, including systems from Cepheid, Quidel, Nanosphere, and others aiming to provide sample to result testing outside central labs.
- Animal diagnostics and emerging metabolomics offerings were other notable areas exhibited by some companies seeking new opportunities beyond traditional human diagnostics.
This document provides an overview and market analysis of the neurointerventional devices market from 2010 to 2017. It states that the global market was estimated at $1.25 billion in 2012 and is expected to grow at a 6.8% compound annual growth rate to $1.73 billion by 2017. The largest segment is aneurysm coiling and arteriovenous malformation embolization and fistula embolization. North America currently dominates the market but Asia-Pacific and Latin America are expected to grow faster due to increasing healthcare spending. The report covers market drivers, trends, competitive landscape and company profiles of major players.
Global Respiratory Care Equipment & Supplies IndustryReportLinker.com
This report analyzes the worldwide markets for Respiratory Care Equipment & Supplies in US$ Million by the following product segments - Pulmonary Function Testing Equipment, Spirometers, Sleep Apnea Diagnostic Devices, Ventilators, Humidifiers, Nebulizers, CPAP/Bi-level Devices, Oxygen Equipment, Manual Resuscitators, and Masks, Circuits & Disposables. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report profiles 223 companies including many key and niche players such as AirSep Corporation, Allied Healthcare Products, Inc., Care Fusion Corporation, Compumedics Ltd., Covidien Ltd., Dr
Similar to Global Cardiovascular Disease Diagnostics Industry (20)
Smartphones: When is the first and last time you check yours?ReportLinker.com
Nearly half (46%) of Americans say they check their smartphones as soon as they wake up, while they’re still in bed, according to ReportLinker’s survey results. This is especially true of Millennials, 66% of whom say it’s the first thing they do before getting out of bed.
75% of Ameircans say they keep their smartphones active all day and night, and a staggering 83% of Millennials say they do.
In fact, disconnecting can be hard. More than half of Americans say their last check is right before bed – and 13% say they disconnect only after they’ve gotten into bed for the night. Even after they fall asleep, about 10% say they’ll wake up and check it during the night.
Interview Co-Founder ReportLinker and Findout, Benjamin CarpanoReportLinker.com
ReportLinker and Findout use data analytics technologies to aggregate and normalize data from a wide range of sources to help researchers and analysts find relevant information more efficiently. The companies' core competency lies in both search and data analytics capabilities. Their natural language processing platform analyzes millions of documents daily to extract and structure concepts, relationships, and sentiments to improve users' productivity. Open data initiatives have helped the businesses by providing more content to incorporate, though most value comes from backend processing rather than raw data access. The companies aim to continue enhancing data discovery and contextualization of results.
This graphic shows Samsung's customers are still loyal: 86% of Samsung Customers would consider Samsung next time they upgrade their smartphone. More info on reportlinker.com/inisght
This document provides a summary of a report on the European branded coffee shop market in 23 countries. Some key points:
- It examines the size and growth of the branded coffee shop market in each country from 2009-2015. Several countries like Poland and Spain saw strong growth over 10% in 2011-2012.
- Market leaders like Starbucks, Costa Coffee and Coffee Fellows are profiled for each country along with operating statistics and strategies. Consumer trends toward convenience and sustainability are also discussed.
- Challenges facing the industry like economic uncertainty and high rents are analyzed. Success factors include quality coffee, food offerings and a strong brand. The growth potential of each market is evaluated based on GDP per capita and existing
Allegra's definitive annual study on the UK branded coffee shop market is now available; with insight from over 25,000 consumers the report provides an authoritative view of the market.Drawing on more than 12 years in-depth research, it is considered to be the bible of the coffee sector.KEY AREAS COVERED' Market size and growth projections for the total UK market' Impact of recent economic downturn on trading performance' Key player profiles, including financial performance, pricing analysis and forecasts' Importance of ethical and sustainability issues' Key success factors and market trends' Opportunities and challenges for suppliers' Consumer coffee consumption patterns' Consumer brand awareness and perceptions of key players' Differences between customer demographics, including age, gender, occupation and location by the reportSOURCE OF INFORMATION' Interviews with CEOs, managing directors, senior managers and store managers of major industry players, including:' leading UK coffee and food-focused chains' major coffee roasters and key equipment suppliers' non-specialist players including department stores, supermarkets, bookstores' leading property companies, letting agents and landlords' local authorities' Online surveys with UK coffee shop visitors' Desk research including: News articles and trade press, the Internet and company websites,industry associations, published accounts, data supplied by operators' In-store observations and analysis
Wireless Infrastructure: Market Shares, Strategies, and Forecasts, Worldwide,...ReportLinker.com
WinterGreen Research announces that it has published a new study Wireless Infrastructure: Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2019. Next generation mission critical systems are leveraging new technology. The 2013 study has 554 pages, 245 tables and figures. Worldwide Wireless Infrastructure markets are poised to achieve significant growth as Building out core networks and backhaul for smart phones.A smart phone is not very smart if the infrastructure can't support its applications. In response to the high growth smart phone markets, wireless infrastructure promises to grow dramatically in the near term.. Wireless Infrastructure technologies include WiMax, LTE, 4G and HSPA. These technologies are driving much higher capacity from the base station back to the fiber core. Fiber core is putting extreme pressure on provider's infrastructure and backhaul networks.WinterGreen Research predicts that the dramatic growth of wireless infrastructure is based on the growth of smart phones to a one trillion market by 2019, serving an installed base of 8.5 billion, many people having more than one smart phone. Wireless infrastructure markets at $58 billion in 2012 will be $163 billion by 2019, new markets evolved because of the value that apps provide to smart phones, mobile devices, tablets, and the Internet of things.According to Susan Eustis, lead author of the study, 'Wireless Infrastructure is being installed to upgrade core networks and upgrade backhaul and base stations to make systems more modern. Infrastructure for the Internet and for smart mobile devices creates demand for more sophisticated web development and web applications that in turn depend on more sophisticated infrastructure. Everything is going mobile. This evolution is driven by mobile smart phones and tablets that provide universal connectivity. Modern systems represent a significant aspect of Internet market evolution.'The proportions of wireless infrastructure market industry segments are expected to remain much as they are, with the small cells and femtocells achieving strong growth on the access side, the core infrastructure must be upgraded to support the added backhaul backbone infrastructure. Wireless apps are expected to achieve $37 trillion revenue by 2019. This unbelievable growth occurs as the Internet is expanded to implement the interconnection of everything.Digital devices proliferate, machine to machine capabilities vastly expand instrumentation. The digital devices become the engine of a world economy, with apps collecting pennies a day for millions of apps from 8.5 billion people with smart phones by 2019.
This document is a fax order form for reports from ReportLinker, which provides industry reports, company profiles, and market statistics. It contains fields for customers to provide contact and billing information as well as select a payment method of credit card, wire transfer, or check in order to place an order for reports. The form directs customers to fax the completed form back to ReportLinker offices in either Europe, the Middle East, and Africa or Asia, Oceania, and America depending on location.
This document is a fax order form for industry reports and company profiles from ReportLinker. It contains fields for customers to provide their contact and shipping information as well as payment details including credit card number, expiration date, and CVV. The form also lists ReportLinker's fax numbers for customers in different regions to submit their orders.
This very short document contains a single word - "TEST" - with no other context provided. It is not possible to provide a meaningful summary in 3 sentences or less given the extremely limited information.
Global Electric Resistance Welded Pipes IndustryReportLinker.com
This report analyzes the worldwide markets for Electric Resistance Welded Pipes in Thousand Tons by the following Product Segments: Mechanical Steel Tubing, Structural Tubing, Structural Steel Pipes, Pressure Tubing, Standard Pipes, Oil Country Tubular Goods, and Line Pipes. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 181 companies including many key and niche players such as Al Jazeera Steel Products Company SAOG, Arabian Pipes Company, ArcelorMittal SA, ERW Pipes Portfolio of ArcelorMittal ChelPipe, Choo Bee Metal Industries Berhad, EVRAZ North America, JFE Steel Corporation, Maharashtra Seamless Limited, Melewar Industrial Group Berhad, Nippon Steel & Sumitomo Metal Corporation, Northwest Pipe Company, OAO TMK, TMK IPSCO, PT Bakrie Pipe Industries, Salzgitter Mannesmann Line Pipe GmbH, Tata Steel Europe, Techint Group SpA, Tenaris S.A., TenarisSiderca, Ternium S.A., United States Steel Corporation, United Metallurgical Company /OMK, Welspun Corp Ltd., Wheatland Tube Company, and Select Products of Wheatland Tube Company. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
This report analyzes the worldwide markets for Wireless Gaming in US$ Million by the following Product Segments: Messaging Based Wireless Gaming, Browser/Web Based Wireless Gaming, and Downloadable Wireless Gaming. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. The report profiles 90 companies including many key and niche players such as Blockdot, Inc., DeNA Co., Ltd., Electronic Arts, Inc., Gameloft SA,GAMEVIL, GREE International, Inc., Glu Mobile Inc., GigaMedia Limited, HandyGames, I-play, Itsmy
Hyperalgesia Global Clinical Trials Review, H1, 2013ReportLinker.com
Hyperalgesia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Hyperalgesia Global Clinical Trials Review, H1, 2013" provides data on the Hyperalgesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hyperalgesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hyperalgesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Genital Herpes Global Clinical Trials Review, H1, 2013ReportLinker.com
Genital Herpes Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Genital Herpes Global Clinical Trials Review, H1, 2013" provides data on the Genital Herpes clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Genital Herpes. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Genital Herpes. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
The Future of Direct Communications Technologies and Proximity-based Applicat...ReportLinker.com
Overview: There are a number of technologies that may be deployed that all provide the ability for devices to "discover" one another, although over different distances ranging from centimeters (Near Field Communications), to meters (Bluetooth), to 10s of meters (Wi-Fi). They also all provide the ability for the devices to communicate directly with one another without a centralized network. Some of these use direct communication as their primary mode of communication e.g. NFC or RFID. Others are more traditional networks which provide direct communication ability as an adjunct to their primary network functions e.g. LTE-Direct or Wi-Fi Direct. Most of the short-term drivers for proximity-based services will be mobile advertising and social networking, especially friend-finder services or dating services, and gaming. In the longer term, other applications will come into play within the scope of the so called Internet of Things. The challenge and opportunity for network operators will be to develop new user scenarios and even new business models to generate revenues from these services. This research uncovers opportunities that will be both beneficial and disruptive to the existing ecosystem and value chain. This research is must reading for any company that is considering offerings within proximity and direct communications and any company that wants to stay ahead of the crowd in terms of preparation for these disruptive technologies. Target Audience: ' Mobile network operators' Industry verticals of all types' Wireless device manufacturers' Network infrastructure companies' Advertising agencies, brands, and merchants' Social networks, advertising, and content providers' Proximity, location, and direct communications vendors Key Report Benefits: ' Market forecasts for each significant technology/solution approach' Recognize the upcoming role and importance of LTE Direct compared to other solutions' Analysis of the major vendors focused on proximity and direct communications solutions' Understand the relationship between proximity, direct communications and the Internet of Things' Understand the technical and business-related differences between proximity/presence and location' Identify each of the major technologies/solutions for proximity detection, location determination, and direct communications' Evaluation of the market for major applications including public safety, social networking, advertising, the Internet of Things, and general location services Select Companies in Report: ' 3M Company' Alcatel-Lucent' iSIGN' LG' Nokia' Samsung' Qualcomm' Verizon Wireless
Competing in the European Molecular Diagnostics Market: France, Germany, Ital...ReportLinker.com
This new 970-page comprehensive five-country report from Venture Planning Group is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods. In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.
Competing in the European Clinical Chemistry and Immunodiagnostic Markets: Fr...ReportLinker.com
This document provides a summary and table of contents for a 900-page report analyzing the clinical chemistry and immunodiagnostic markets in five major European countries. The report explores trends, evaluates competitors, and identifies opportunities in these evolving markets. It contains estimates of test volumes, sales forecasts by category and country, and competitive profiles of leading suppliers.
Bradycardia Global Clinical Trials Review, H1, 2013ReportLinker.com
Bradycardia Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Bradycardia Global Clinical Trials Review, H1, 2013" provides data on the Bradycardia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bradycardia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bradycardia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013
Summary
GlobalData's clinical trial report, 'Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2013" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acid Indigestion / Heartburn/ Pyrosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
This document is a report on the China iron ore mining industry in 2013. It provides an overview of the industry, including its definition and development history. It analyzes the macroeconomic environment and discusses factors like policy, upstream/downstream industries. It also examines the international and domestic markets. Key data on the industry from 2008-2012 is presented, including numbers of enterprises, employees, assets, output, sales, profits and trade. The competitive landscape and strategies of major companies are evaluated. The report concludes with discussions of development trends, investment environment and new technologies in the industry.
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
The Evolution and Impact of OTT Platforms: A Deep Dive into the Future of Ent...ABHILASH DUTTA
This presentation provides a thorough examination of Over-the-Top (OTT) platforms, focusing on their development and substantial influence on the entertainment industry, with a particular emphasis on the Indian market.We begin with an introduction to OTT platforms, defining them as streaming services that deliver content directly over the internet, bypassing traditional broadcast channels. These platforms offer a variety of content, including movies, TV shows, and original productions, allowing users to access content on-demand across multiple devices.The historical context covers the early days of streaming, starting with Netflix's inception in 1997 as a DVD rental service and its transition to streaming in 2007. The presentation also highlights India's television journey, from the launch of Doordarshan in 1959 to the introduction of Direct-to-Home (DTH) satellite television in 2000, which expanded viewing choices and set the stage for the rise of OTT platforms like Big Flix, Ditto TV, Sony LIV, Hotstar, and Netflix. The business models of OTT platforms are explored in detail. Subscription Video on Demand (SVOD) models, exemplified by Netflix and Amazon Prime Video, offer unlimited content access for a monthly fee. Transactional Video on Demand (TVOD) models, like iTunes and Sky Box Office, allow users to pay for individual pieces of content. Advertising-Based Video on Demand (AVOD) models, such as YouTube and Facebook Watch, provide free content supported by advertisements. Hybrid models combine elements of SVOD and AVOD, offering flexibility to cater to diverse audience preferences.
Content acquisition strategies are also discussed, highlighting the dual approach of purchasing broadcasting rights for existing films and TV shows and investing in original content production. This section underscores the importance of a robust content library in attracting and retaining subscribers.The presentation addresses the challenges faced by OTT platforms, including the unpredictability of content acquisition and audience preferences. It emphasizes the difficulty of balancing content investment with returns in a competitive market, the high costs associated with marketing, and the need for continuous innovation and adaptation to stay relevant.
The impact of OTT platforms on the Bollywood film industry is significant. The competition for viewers has led to a decrease in cinema ticket sales, affecting the revenue of Bollywood films that traditionally rely on theatrical releases. Additionally, OTT platforms now pay less for film rights due to the uncertain success of films in cinemas.
Looking ahead, the future of OTT in India appears promising. The market is expected to grow by 20% annually, reaching a value of ₹1200 billion by the end of the decade. The increasing availability of affordable smartphones and internet access will drive this growth, making OTT platforms a primary source of entertainment for many viewers.
Industrial Tech SW: Category Renewal and CreationChristian Dahlen
Every industrial revolution has created a new set of categories and a new set of players.
Multiple new technologies have emerged, but Samsara and C3.ai are only two companies which have gone public so far.
Manufacturing startups constitute the largest pipeline share of unicorns and IPO candidates in the SF Bay Area, and software startups dominate in Germany.
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Best practices for project execution and deliveryCLIVE MINCHIN
A select set of project management best practices to keep your project on-track, on-cost and aligned to scope. Many firms have don't have the necessary skills, diligence, methods and oversight of their projects; this leads to slippage, higher costs and longer timeframes. Often firms have a history of projects that simply failed to move the needle. These best practices will help your firm avoid these pitfalls but they require fortitude to apply.
Tata Group Dials Taiwan for Its Chipmaking Ambition in Gujarat’s DholeraAvirahi City Dholera
The Tata Group, a titan of Indian industry, is making waves with its advanced talks with Taiwanese chipmakers Powerchip Semiconductor Manufacturing Corporation (PSMC) and UMC Group. The goal? Establishing a cutting-edge semiconductor fabrication unit (fab) in Dholera, Gujarat. This isn’t just any project; it’s a potential game changer for India’s chipmaking aspirations and a boon for investors seeking promising residential projects in dholera sir.
Visit : https://www.avirahi.com/blog/tata-group-dials-taiwan-for-its-chipmaking-ambition-in-gujarats-dholera/
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...my Pandit
Dive into the steadfast world of the Taurus Zodiac Sign. Discover the grounded, stable, and logical nature of Taurus individuals, and explore their key personality traits, important dates, and horoscope insights. Learn how the determination and patience of the Taurus sign make them the rock-steady achievers and anchors of the zodiac.
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
Global Cardiovascular Disease Diagnostics Industry
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Global Cardiovascular Disease Diagnostics Industry
Published on February 2011
Report Summary
This report analyzes the worldwide markets for Cardiovascular Disease Diagnostics in US$ Million by the following product segments
- Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for
these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East,
and Latin America. The report profiles 71 companies including many key and niche players worldwide such as AccuTech, LLC, Abbott
Diagnostics, Alere Inc., Biosite, Inc., Ani Biotech Oy, Axis-Shield PoC, Beckman Coulter, Inc., biomérieux, Cambridge Heart, Inc.,
Cholestech Corp., GE HealthCare, Home Access Health Corporation, LifeSign LLC, Liposcience, Inc., Nanosphere, Inc.,
Ortho-Clinical Diagnostics, Inc., Philips Healthcare, Polymer Technology Systems, Inc., Response Biomedical Corp., Roche
Diagnostics, Siemens Healthcare Diagnostics, Inc., St. Jude Medical, Inc., and EP MedSystems. Market data and analytics are
derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online
sources.
Table of Content
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions and Scope of Study 3
In Vitro Diagnostics 3
In Vivo Diagnostics 3
2. INDUSTRY OVERVIEW 5
Cardiovascular Diseases: The Undying Challenge 5
Table 1: Region-Wise Incidence and Prevalence of
Cardiovascular Diseases in 2006 6
Mounting Healthcare Costs - Calls for Early Diagnosis 6
Cardiovascular Disease Diagnostics: Playing a Pivotal Role in
Early Disease Detection 6
Developed Countries Dominate, Developing to be the Future
Growth Engine 7
Fast and Accurate Diagnosis - Reduce Unnecessary Healthcare Costs 7
POC Diagnostics Market Gains Momentum 8
Cardiac Markers - Making Diagnosis Easier and Quicker 8
Global Cardiovascular Disease Diagnostics Industry Page 1/21
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Major Cardiac Markers and their Properties 9
What's New in POC Cardiac Markers Space' 9
Leading Players 10
List of Point of Care Cardiac Marker Testing Products 10
3. IN-VIVO DIAGNOSTICS 11
Table 2: Global In-vivo Cardiovascular Disease Diagnostics
Market by Region: 2010 (includes corresponding Graph/Chart) 11
Novel Imaging Techniques Boost In vivo Diagnostics Market 11
Non-Invasive Procedure Hogs the Limelight for Cardiovascular
Treatment 12
Cardiology Diagnostic Imaging 12
New Technologies Bring Diagnostics Closer to Patients 12
Trends Cited in the Imaging Technologies Market 13
CT Scanners 13
MRI 14
Move Towards Efficient Patient Data Management 14
4. IN-VITRO DIAGNOSTICS 15
A Quick Insight into the Global In-vitro Diagnostics Market 15
Growth Trends 15
Developed Countries Drive In-Vitro Diagnostics (IVD) Market 15
Table 3: Leading In-Vitro Diagnostics Markets Worldwide
(2007): Percentage Breakdown for North America, Europe,
Japan, and Others (includes corresponding Graph/Chart) 16
Established Players Dominate the Fragmented Market 16
Table 4: Leading Players in the Global In-Vitro Diagnostics
Market (2009): Percentage Breakdown of Value Sales for Roche
Diagnostics, Abbott Diagnostics, Ortho/ LifeScan,
Bayer/Siemens, Beckman Coulter, BD, Dade Behring, bioMerieux
and Others (includes corresponding Graph/Chart) 16
Point-of-Care In-Vitro Testing on the Roll 17
Table 5: Global In vitro Diagnostics Market by Type of Test
(2007): Percentage Breakdown for Central Lab Testing,
Point-of-Care Testing, and Molecular Testing (includes
corresponding Graph/Chart) 17
A Specific Focus on Global Cardiovascular In-Vitro Diagnostics
Market 17
Market Analysis 18
Table 6: World Cardiovascular In-vitro Diagnostics Market:
2010 (includes corresponding Graph/Chart) 18
Aging Population Drives Home Testing Market 18
Cholesterol and Other Cardiovascular Test Kits Offered by
Leading Companies 19
Development of Home Cholesterol Testing Kits 19
Table 7: Global Cholesterol Point-of-Care Rapid Tests Market
(2009): Market Shares of Leading Players by Value Sales for
Inverness Medical, Roche, Abaxis, and Others (includes
corresponding Graph/Chart) 19
Strong Demand for Risk Assessment Markers 19
Global Cardiovascular Disease Diagnostics Industry Page 2/21
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Advancements in Alternate-Site Coagulation Monitoring 20
5. CVD - CAUSE AND RISK FACTORS 21
CVD - Global Facts 21
Table 8: CVD Death Rates (per 100,000 population) Among Men
(Aged 35-74 years) by Select Country: 2007 (includes
corresponding Graph/Chart) 21
Table 9: CVD Death Rates (per 100,000 population) Among Women
(Aged 35-74 years) by Select Country: 2007 (includes
corresponding Graph/Chart) 22
Atherosclerosis - Leading Cause for CVD 22
Risk Factors 22
Irreversible Risk Factors 22
Increasing age 22
Sex (gender) 23
Heredity (including Race) 23
Risk Factors that can be controlled 23
Tobacco Smoke 23
High Blood Cholesterol 23
LDL Cholesterol 24
HDL Cholesterol 24
Triglyceride levels 24
Hypercholesterolemia - Conditions Associated with
Cholesterol Level 25
High Blood Pressure 25
BP - Leading Cause of Cardiovascular Disease in Young Adults 26
Physical Inactivity 26
Obesity and Overweight 26
Diabetes Mellitus 26
Cardiovascular Disease and Homocysteine Levels 26
Measures for Reducing Cardiovascular Diseases 27
6. CARDIOVASCULAR DISEASE AND CONDITIONS 28
Angina Pectoris 28
Arrhythmias 28
Sudden Cardiac Death (SCD) 28
Stroke 28
Congestive Heart Failure 29
Heart Failure Classification as per the NYHA and ACC/AHA 29
Table 10: Prevalence Rates of Congestive Heart Failure in
Select Countries (per 10,000) (includes corresponding
Graph/Chart) 30
Cardiovascular Disease Involving Transplant Patients 30
7. DIAGNOSTIC TESTS FOR CARDIOVASCULAR DISEASES 31
In-Vitro Cardiovascular Diagnostics 31
Cholesterol Testing 31
Use of Markers 31
Creatine Kinase MB 31
Global Cardiovascular Disease Diagnostics Industry Page 3/21
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Troponin T and Troponin I 32
C-Reactive Protein 32
Plasminogen Activator Inhibitor-1 33
D-Dimer 33
Thrombus Precursor Protein 33
Other Cardiac Markers 33
Increasing Popularity of Risk Assessment Markers 33
A Step Forward in Cardiovascular Risk Assessment 34
In Vivo Diagnostic Tests 34
Computed Imaging / Tomography 34
Electron Beam Computed Tomography (EBCT) 34
Appropriate Conditions for EBCT Diagnosis 35
Cardiac Positron Emission Tomography (PET) 35
Digital Cardiac Angiography/ Digital Subtraction Angiography 36
Magnetic Resonance Imaging (MRI) 36
Single Photon Emission Computed Tomography (SPECT) 37
Echocardiography 37
Different Types of Echo-techniques 37
M-mode (Motion mode, One-dimensional) 37
Two-Dimensional (Cross-sectional) 38
Stress Echocardiogram (Stress Echo) 38
Transesophageal Echocardiogram (TEE) 38
Risks 38
Ultrasound Tests 38
Doppler Ultrasound 38
Intravascular Ultrasound 39
Working 39
Comparative Facts Related to Definitive Diagnosis of
Cardiovascular Disease 39
Nuclear Cardiology Tests 40
Applications 40
Types of Nuclear Cardiology Tests 40
Myocardial Perfusion Imaging 40
Applications 41
Risks 41
Ventricular Function Test 41
Testing Cardiac Stress 42
Cardio Vascular Disease Diagnostics Tests in the Pipeline 42
Aderis MRE-0470 42
CardioMEMS Novel Technology 42
Technology Platform 42
8. PRODUCT LAUNCHES AND DEVELOPMENTS 43
Cardiac Science Launches Microvolt T-Wave Alternans Module 43
Cleveland HeartLab to Extend Test Menu 43
St. Jude Medical Introduces EnSite Derexi Module 43
NorDiag Unveils NorDiags Arrow Instrument 44
Biosense Webster Launches CARTO® 3 System 44
McKesson Unveils New Variant of Horizon Cardiology
Cardiovascular Information System 44
Global Cardiovascular Disease Diagnostics Industry Page 4/21
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Correlagen Launches CardioGeneScan Test 44
Royal Philips Electronics to Launch PageWriter TC50 Cardiograph 45
Philips Introduces Xcelera R3.1 45
St. Jude Medical Launches Medical Devices for Heart Rhythms
Disorders 45
TomTec and Medis Launches Cardiac Imaging and Analysis Product 46
Royal Philips Electronics Launches PageWriter TC70 46
Philips Healthcare to Introduce CX50 CompactXtreme 47
Royal Philips Electronics Introduces Xcelera R2.2 47
Toshiba America to Launch AplioTM Artida 47
9. PRODUCT LAUNCHES AND DEVELOPMENTS IN THE RECENT PAST - A
PERSPECTIVE BUILDER 49
Philips Rolls Out 256-slice CT scanner, Brilliance iCT Scanner 49
Royal Philips Launches Live 3D Transesophageal Echocardiogram
Probe 49
GE Healthcare Launches Vivid e Ultrasound Systems 49
Cardionetics Launches ECG Monitor for 24-Hour Real-Time
Cardiac Diagnosis 49
Siemens Launches Imaging Release for the ACUSON Sequoia Platform 50
GE Healthcare Launches Version 2.0 of Centricity Cardiology
CA1000 50
GE Healthcare Introduces New Capabilities to CardioSoft
Diagnostic Software 50
GE Healthcare's Lightspeed VCT Offers Imaging at 70% Lower
Exposure 50
Roche Diagnostics Launches cobas h 232 Portable Cardiac Marker
System (Outside US) 51
Royal Philips Launches New Imaging Tool for Complex Cardiac
Arrhythmias 51
Siemens Medical Introduces syngo® US, New Echocardiography
Solution. 51
Dade Behring Introduces CardioPhase® hsCRP Test for Multiple
Testing Platforms. 51
Shimadzu Launches Two Models in Angiographic Imaging 52
Omron Healthcare Introduces Non Invasive Vascular Profiling
System 52
Abbott Launches XIENCE V, New Coronary Stent System 52
Siemens Medical Introduces Acuson AcuNav 8F, an Advanced
Ultrasound Catheter 52
BioMérieux Introduces High Performance VIDAS Troponin I Ultra 53
Siemens Launches Acuson X300 Ultrasound Platform 53
Siemens Releases Web-Enabled CT 53
GE Introduces Latest Electrocardiograph Device, MAC 3500 54
GE Emphasizes on the Striking Features of New Vivid 7
Dimension '06 54
GE Launches Latest Innova Digital Flat Panel Biplane Imaging
Devices 54
Medtronic Introduces Latest Range of Implantable Cardiac
Defibrillators 55
Global Cardiovascular Disease Diagnostics Industry Page 5/21
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Philips Introduces Web Based Cardiac Tools 55
Siemens Showcases Solutions for Cardiac Problems Through
Molecular Imaging 55
Siemens Presents Advancements in Echocardiography 55
Siemens Debuts syngo BEAT 56
Siemens Combines syngo® Dynamics with Soarian® for
Cardiovascular EPR 56
GE Healthcare Unveils CardIQ Fusion 56
GE Introduces Discovery VCT 56
GE Unveils Dynamic VUE 56
GE Launches CardIQ Xpress 57
GE Presents the Ventri for Cardiac Imaging 57
GE Introduces High Definition Magnetic Resonance System 57
Dade Behring Unveils CardioPhase(R) hsCRP Test 57
Siemens Launches Encompass III on C512 Ultrasound Platform 57
Siemens Launches Four New CT Clinical Engines 58
Omron Launches HEM-9000AI Cardiovascular Diagnostic Tool 58
Corgenix Introduces Predictive Cardiovascular Diagnostic Kit,
AtherOx' 58
Philips Introduces HD11 XE Cardiology Ultrasound System 58
Siemens Introduces Biplane FD Cardiology System 59
Siemens Introduces Syngo Circulation Software for CT Tomography 59
Siemens Introduces SOMATOM Definition for Cardiac Imaging 59
Dade Behring Unveils Homocysteine Test on BN (TM) Systems 59
Roche Unveils Cardiac pro-BNP Test 59
Philips Introduces HD11 XE 60
Corgenix Unveils AtherOx(TM) 60
GE Healthcare Unveils Breakthrough Imaging Technology 60
Philips Launches Products to Detect Heart Problems 60
Philips Unveils Computed Tomography and EP Planning package 61
Philips Widens Magnetic Resonance Portfolio 61
New Cardiac Monitoring Products from Philips 61
Siemens Launches Image-Arena 61
Siemens Announces New Procam-Calculator Combined with CT
Examination 61
Siemens Medical Solutions Launches Axiom Artis dTA 62
GE Healthcare Unveils Vivid i 62
GE Healthcare Presents Fully Integrated 4D Cardiovascular
Ultrasound System 63
GE Healthcare Debuts New Imaging System 63
New Discovery PET/CT Systems from GE Healthcare 63
SonoSite Presents SonoCalc IMT Software 63
Dade Behring Introduces High Sensitivity Troponin I Assay 64
Biosite Unveils New Diagnostic Test 64
MDS Diagnostic Services Unveils New Test to Prevent Heart Disease 64
diaDexus Develops PLAC Test 65
Siemens Introduces New Nuclear Cardiology Imaging System 65
Roche Diagnostics Receives U.S. Clearance and European CE Mark 65
Camtronics Unveils Cardiovascular Screening Software 66
Mayo Pioneers New Enzyme-Based Cardiovascular Risk Assessment
Global Cardiovascular Disease Diagnostics Industry Page 6/21
7. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Test 66
10. RECENT INDUSTRY ACTIVITY 67
Inverness Changes Name to Alere 67
Miraculins Acquires PreMD's PREVU(i) Skin Cholesterol Test Assets 67
Kardia Health Systems Partners with TomTec Imaging Systems 67
TriLink and Biofortuna Ink Licensing Agreement 67
Corgenix Enters into a Strategic Alliance with ELITech 68
VaxGen to Merge with diaDexus 68
St. Jude Medical to Take Over LightLab Imaging 68
GE Healthcare and CardioDx Enter into Strategic Alliance 69
bioMerieux and Knome Ink Strategic Partnership Agreement 69
Merge Healthcare Acquires AMICAS 69
Diamedix and Nova Ink Distribution Agreement 70
Inverness Acquires Standard Diagnostics 70
Quidel Acquires Diagnostic Hybrids 70
bioMérieux Acquires Meikang Biotech 70
Aurora Health Care Partners with Celera 71
Mediscience Technology Corporation Acquires SensiVida Medical
Systems 71
Volcano Acquires Axsun Technologies 71
Thermo Fisher Takes Over B.R.A.H.M.S. 71
SonoSite Acquires CardioDynamics International 72
IntriCon Snaps Up Datrix 72
ST. Jude Medical Receives US FDA and European Approval for
EnSite Velocity' Cardiac Mapping System 72
Roche Inks Agreement with Response Biomedical 72
Dynatek Dalta Scientific Inks Agreement with State Food and
Drug Administration 73
Amic Inks Licensing Deal with Roche Diagnostics 73
TRICARE Includes Atherotech's VAP® Test 73
PreMD Receives NSE Letter from US FDA for POC Skin Cholesterol
Test 74
Amic Gains License for Roche's Cardiac Marker 74
diaDexus and Fisher HealthCare Sign Agreement 74
Inverness Inks Distribution Agreement with PrognostiX 75
GE Healthcare Enters into Collaboration with Boston Scientific 75
St. Jude Medical Acquires EP MedSystems 75
11. INDUSTRY ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER 76
Inverness Takes Over Biosite 76
Siemens Medical Acquires Dade Behring 76
Inverness Medical Innovations Acquires Cholestech 76
Acrongenomics, Pearson and Molecular Enter into Joint Venture 77
Cholestech Teams Up with Onsite Health Diagnostics 77
Lipomics to Collaborate with Agilent Technologies to Develop
Diagnostic Tests. 77
Transgenomic and Fiuotecnica Renew Collaboration Agreement 78
Alteon and BioRap Technologies Enter into an Agreement 78
IM Medical Acquires New Technology for Detecting
Global Cardiovascular Disease Diagnostics Industry Page 7/21
8. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Cardiovascular Diseases 78
Medtronic Establishes New Business Entity 78
Siemens Medical Acquires Bayer Healthcare's Diagnostics Unit 79
Inverness Medical Innovations Completes Acquisition of HemoSense 79
Spacelabs Acquires Ferraris' Cardiac Unit 79
Global Immune Takes over Primedical International 80
Siemens Acquires Diagnostics Products 80
Cholestech and Life Line Enter into Collaboration 80
LipoScience Signs an Agreement with ARUP 80
Philips Acquires Witt Biomedical 80
CardioDynamics Enters into an OEM Agreement with Shenzhen Mindray 81
Biosense Enters into Strategic Partnership with Siemens
Medical Solutions 81
Dade Behring Approved the Use of FSAP Antibodies by American
Diagnostica 81
Abbott Receives Non-exclusive Sublicense for Diagnostic Use of
PIGF 81
Nanogen Acquires Spectral's Cardiac Test Division 82
Varian Enters into Alliance with LipoScience to Jointly
Develop NMR System 82
Cardiac Services Professionals Establish eCardio Diagnostics 82
Response Biomedical Wins Nonexclusive License Rights for NT-
proBNP and Troponin T 83
Biomerieux gains Nonexclusive License for NT-proBNP 83
Philips and PMI Ink an Agreement for Outpatient Facility 83
LipoScience Enters into an Agreement with LabCorp 83
Abbott and Cleveland Clinic to Co-develop Myeloperoxidase
Cardiac Test 83
Abbott Receives 510(k) Clearance from FDA for Myoglobin Test 84
FDA Clears Additional Claim for Biosite's Triage (R) BNP Test 84
Biosite Inks an Agreement with University of Mainz 84
Dade Behring Receives FDA Clearance for Advanced D-Dimer Assay 84
Nanogen Acquires SYN'X Pharma 84
GE Takes Over Amersham Plc 85
St. Jude Medical Acquires Irvine Biomedical and Epicor 85
SonoSite Snaps Up SonoMetric 85
CardioDynamics Acquires Vermed 85
Philips and EP MedSystems Announce an Alliance Involving
Electrophysiology Solutions 85
Toshiba and ViTAL Enters into an Alliance with Johns Hopkins
University School of Medicine 85
Response Biomedical Collaborates with Shionogi 86
Terumo Signs Agreement with Spencer Technologies 86
Spectral Diagnostics Announces Agreement with NGC Medical 86
Philips Signs Agreement with Fletcher Allen Health Care 86
Spectral Diagnostics Enters into an Agreement with Cardinal
Health 86
Siemens Signs Agreement with MediGuide 86
Biosite Enters into Agreement with DMI BioSciences 87
Cambridge Heart Enters into Agreement with Del Mar Reynolds 87
Global Cardiovascular Disease Diagnostics Industry Page 8/21
9. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Cholestech Enters into an Agreement with Itamar Medical 87
Siemens Enters into a Contract with HiPGraphics 87
Abbott Announces US Clearance for Axis-Shield's BNP Test for
Use on AxSYM 88
Cholestech Announces FDA 510(k) Approval for hs-CRP Test 88
Dade Behring Bags FDA Clearance NT-proBNP Test 88
Dade Behring Receives FDA Clearance for N High Sensitivity CRP
Assay 88
EP-4 Computerized Cardiac Stimulator Bags FDA Approval 88
Biosite Adds two new offices 88
Bayer Diagnostics Enhances BNP Assay Offering Globally 89
EP MedSystems Garners CE Approval for ALERT Deflectable CS
Catheter in Europe 89
Cambridge Heart Inc. and Quinton Cardiology Systems Renew Pact 89
EPIX and Schering AG Extends Collaboration Agreement 90
Siemens Ultrasound and TomTec Imaging Systems Announces Agreement 90
FIT Biotech Plc Acquires Xenerate Ab to Develop Innovative
Cardiovascular Devices 90
Beckman Coulter Enters into Agreement with Biosite 90
Dade Behring Garners Non-exclusive Rights for a Key Cardiac
Marker 91
Bracco Diagnostics Inc., Joins Hand with Eastern Isotopes Inc
to Develop CardioGen-82® 91
New Lab Test from diaDexus Receives FDA Clearance 91
Hypertension Diagnostics Receives SDA Approval in China 91
12. FOCUS ON SELECT GLOBAL PLAYERS 92
AccuTech, LLC (USA) 92
Abbott Diagnostics (USA) 92
Alere Inc. (USA) 92
Biosite, Inc. (USA) 94
Ani Biotech Oy (Finland) 94
Axis-Shield PoC (UK) 94
Beckman Coulter, Inc. (USA) 95
biomérieux (France) 95
Cambridge Heart, Inc. (USA) 95
Cholestech Corp. (USA) 96
GE HealthCare (UK) 96
Home Access Health Corporation (USA) 97
LifeSign LLC (USA) 97
Liposcience, Inc. (USA) 97
Nanosphere, Inc. (USA) 98
Ortho-Clinical Diagnostics, Inc. (USA) 98
Philips Healthcare (USA) 98
Polymer Technology Systems, Inc. (USA) 99
Response Biomedical Corp. (Canada) 99
Roche Diagnostics (Switzerland) 100
Siemens Healthcare Diagnostics, Inc. (USA) 100
St. Jude Medical, Inc. (USA) 101
EP MedSystems (USA) 101
Global Cardiovascular Disease Diagnostics Industry Page 9/21
10. Find Industry reports, Company profiles
ReportLinker and Market Statistics
13. GLOBAL MARKET PERSPECTIVE 102
Table 11: World Recent Past, Current & Future Market Analysis
for Cardiovascular Disease Diagnostics by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 102
Table 12: World Historic Review for Cardiovascular Disease
Diagnostics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East, and Latin America
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 103
Table 13: World 11-Year Perspective for Cardiovascular Disease
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets for
Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 104
Table 14: World Recent Past, Current & Future Market Analysis
for Cardiovascular In Vitro Diagnostics by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 105
Table 15: World Historic Review for Cardiovascular In Vitro
Diagnostics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Middle East and Latin America
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 106
Table 16: World 11-Year Perspective for Cardiovascular In
Vitro Diagnostics by Geographic Region - Percentage Breakdown
of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets for
Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 107
Table 17: World Recent Past, Current & Future Market Analysis
for Cardiovascular In Vivo Diagnostics by Geographic Region -
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Middle East and Latin America Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015 (includes corresponding Graph/Chart) 108
Table 18: World Historic Review for Cardiovascular In Vivo
Diagnostics by Geographic Region - US, Canada, Japan, Europe,
Global Cardiovascular Disease Diagnostics Industry Page 10/21
11. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Asia-Pacific (excluding Japan), Middle East and Latin America
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 109
Table 19: World 11-Year Perspective for Cardiovascular In Vivo
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Middle East and Latin America Markets for
Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 110
14. THE UNITED STATES 111
A.Market Analysis 111
Trends and Issues 111
Innovations Drive the Usage of Cardiovascular Monitoring
Systems 111
Cholesterol POCT Market: An Overview 111
Table 20: US Cholesterol Point-of-Care Testing (2009):
Market Shares of Leading Players by Value Sales for
Inverness Medical, Polymer Technology Systems, and Roche
Diagnostics (includes corresponding Graph/Chart) 112
Increasing Cardiovascular Ailments Drive Sales of Home Test
Devices 112
CHF Biomarkers to Spearhead the US market 112
Table 21: US AMI (Acute Myocardial Infarction) Diagnostics
Market: Market Share by Revenue held by Major Players
(Dade Behring, Beckman Coulter, Bayer Diagnostics, and
Others) in 2006 (includes corresponding Graph/Chart) 113
Table 22: US CHF (Congestive Heart Failure) Diagnostics
Market: Market Share by Revenue held by Major Players
(Dade Behring, Beckman Coulter, Bayer Diagnostics, and
Others) in 2006 (includes corresponding Graph/Chart) 113
Cardiovascular Disease Prevalence in the US 113
Key Statistics on Cardiovascular Diseases 114
Mortality Statistics 114
Table 23: Prevalence of Cardiovascular Disease in the US
(2004): A Historic Review (includes corresponding
Graph/Chart) 115
Table 24: Percentage Breakdown of Deaths from
Cardiovascular Diseases in the US (2004): A Historic Review
(includes corresponding Graph/Chart) 115
Table 25: Prevalence of Cardiovascular Diseases among
Americans by Age (Age 20 and Older) and Sex (2004): A
Historic Review (includes corresponding Graph/Chart) 116
Table 26: A Factoid of CHD and MI (In Million) in the US
(2003): A Historic Review 116
Global Cardiovascular Disease Diagnostics Industry Page 11/21
12. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Startling facts related to Stroke in US 116
Table 27: A Factoid of Stroke (In Million) in the US
(2003): A Historic Review 117
Incidence of Coronary Heart Disease 117
AHA Statistics for Coronary Heart Disease 117
Mortality rates of CHD 118
Table 28: Annual Number of Americans Having Diagnosed
Heart Attack by Age and Sex (2004) (includes corresponding
Graph/Chart) 118
Table 29: Prevalence of CHD by Age and Sex (2004) (In %
population) (includes corresponding Graph/Chart) 119
Arrhythmias 119
CAD Diagnostics 119
PVD Diagnostics 120
Medicare Reimbursement Set for CPT Code 83704 120
Competitive Glance 120
Point-of-Care (POC) Diagnostics Market in the US 120
Table 30: Leading Players in the US POC Cardiac Market
(2004) - Percentage Breakdown by Value Sales for Biosite,
Dade Behring, Spectral Diagnostics, Roche and Others
(includes corresponding Graph/Chart) 121
B.Market Analytics 121
Table 31: US Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 121
Table 32: US Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 122
Table 33: US 11-Year Perspective for Cardiovascular Disease
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for In Vitro Diagnostics and In Vivo
Diagnostics Markets for 2005, 2010 & 2015 122
15. CANADA 123
A.Market Analysis 123
Cardiovascular Disease Facts 123
B.Market Analytics 123
Table 34: Canadian Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Product Segment -
In Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Global Cardiovascular Disease Diagnostics Industry Page 12/21
13. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Graph/Chart) 123
Table 35: Canadian Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 124
Table 36: Canadian 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 124
16. JAPAN 125
Market Analysis 125
Table 37: Japanese Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Product Segment -
In Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 125
Table 38: Japanese Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 126
Table 39: Japanese 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 126
17. EUROPE 127
A.Market Analysis 127
In Vivo Diagnostics - Major Segment in CVD Diagnostics Market 127
Germany - The Largest European Market 127
Cardiovascular Disease - Mortality Statistics 127
Table 40: Leading Cause of Death Among Men in Europe
(2007): Percentage Breakdown for Cardiovascular Diseases,
Poisoning and Injuries, Respiratory Disease, Cancer, and
Others (includes corresponding Graph/Chart) 128
Table 41: Leading Cause of Death Among Women in Europe
(2007): Percentage Breakdown for Cardiovascular Diseases,
Poisoning and Injuries, Respiratory Disease, Cancer, and
Others (includes corresponding Graph/Chart) 128
Cardiovascular Disease - Risk Factor Profile 128
The Cardiovascular Disease Cost Burden 129
B.Market Analytics 129
Global Cardiovascular Disease Diagnostics Industry Page 13/21
14. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Table 42: European Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Geographic Region
- France, Germany, Italy, UK, Spain, Russia & Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 129
Table 43: European Historic Review for Cardiovascular
Disease Diagnostics by Geographic Region - France, Germany,
Italy, UK, Spain, Russia & Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2000 through 2006 (includes corresponding
Graph/Chart) 130
Table 44: European Recent Past, Current & Future Analysis
for Cardiovascular Disease Diagnostics by Product Segment -
In Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 131
Table 45: European Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 132
Table 46: European 11-Year Perspective for Cardiovascular
Diagnostics by Geographic Region - Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK, Spain, Russia &
Rest of Europe Markets for Years 2000, 2007 & 2010 (includes
corresponding Graph/Chart) 133
Table 47: European 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 133
17a. FRANCE 134
Market Analysis 134
Table 48: French Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 134
Table 49: French Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Global Cardiovascular Disease Diagnostics Industry Page 14/21
15. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 135
Table 50: French 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 135
17b. GERMANY 136
Market Analysis 136
Table 51: German Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 136
Table 52: German Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 137
Table 53: German 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 137
17c. ITALY 138
Market Analysis 138
Table 54: Italian Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 138
Table 55: Italian Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 139
Table 56: Italian 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 139
17d.THE UNITED KINGDOM 140
A.Market Analysis 140
Global Cardiovascular Disease Diagnostics Industry Page 15/21
16. Find Industry reports, Company profiles
ReportLinker and Market Statistics
UK Cardiovascular Diseases Fact Sheet 140
B.Market Analytics 141
Table 57: UK Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 141
Table 58: UK Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 142
Table 59: UK 11-Year Perspective for Cardiovascular Disease
Diagnostics by Product Segment - Percentage Breakdown of
Dollar Sales for In Vitro Diagnostics and In Vivo
Diagnostics Markets for 2005, 2010 & 2015 142
17e. SPAIN 143
Market Analysis 143
Table 60: Spanish Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 143
Table 61: Spanish Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 144
Table 62: Spanish 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 144
17f.RUSSIA 145
A.Market Analysis 145
Major Players 145
B.Market Analytics 146
Table 63: Russian Recent Past, Current & Future Analysis for
Cardiovascular Disease Diagnostics by Product Segment - In
Vitro Diagnostics and In Vivo Diagnostics Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) 146
Global Cardiovascular Disease Diagnostics Industry Page 16/21
17. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Table 64: Russian Historic Review for Cardiovascular Disease
Diagnostics by Product Segment - In Vitro Diagnostics and In
Vivo Diagnostics Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2006
(includes corresponding Graph/Chart) 147
Table 65: Russian 11-Year Perspective for Cardiovascular
Disease Diagnostics by Product Segment - Percentage
Breakdown of Dollar Sales for In Vitro Diagnostics and In
Vivo Diagnostics Markets for 2005, 2010 & 2015 147
17g. REST OF EUROPE 148
Market Analysis 148
Table 66: Rest of Europe Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 148
Table 67: Rest of Europe Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 149
Table 68: Rest of Europe 11-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 &
2015 149
18. ASIA PACIFIC 150
A.Market Analysis 150
Cardiovascular Market in Asia-Pacific 150
China 150
Healthcare Expenditure to Grow Considerably by 2015 150
In vitro Diagnostics Market Poised for Strong Growth 151
Domestic Manufacturers Pose a Threat for Overseas IVD
Manufacturers 151
Leading Players 151
Cardiovascular Disease Patients Overview 151
Treatment Providers and Hospitals Overview 152
Hospitals 152
Table 69: Cardiovascular Special Treatment Hospitals in
China: 1991-2011(In numbers) (includes corresponding
Graph/Chart) 152
Chinese Cardiovascular Disease Treatment as a Part of
Overall Health Care Industry 152
Table 70: Cardiovascular Disease Treatment in China:
Global Cardiovascular Disease Diagnostics Industry Page 17/21
18. Find Industry reports, Company profiles
ReportLinker and Market Statistics
1991-2006 (includes corresponding Graph/Chart) 153
B.Market Analytics 153
Table 71: Asia-Pacific Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 153
Table 72: Asia-Pacific Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 154
Table 73: Asia-Pacific 11-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 &
2015 154
19. THE MIDDLE EAST 155
Market Analysis 155
Table 74: The Middle East Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) 155
Table 75: The Middle East Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 156
Table 76: The Middle East 11-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2005, 2010 &
2015 156
20. LATIN AMERICA 157
A.Market Analysis 157
Brazil: A Growing Market for IVD 157
Table 77: Brazilian IVD Market by Segment (2009):
Percentage Share Breakdown for Immunoassay, Hormone,
Microbiology, Biochemistry, Hematology, Molecular
Diagnostics, Cardiac markers, Hemostasis, and Cytology
(includes corresponding Graph/Chart) 157
Global Cardiovascular Disease Diagnostics Industry Page 18/21
19. Find Industry reports, Company profiles
ReportLinker and Market Statistics
B.Market Analytics 158
Table 78: Latin American Market for Cardiovascular Disease
Diagnostics - Recent Past, Current & Future Market Analysis
by Product Segment for In Vitro Diagnostics and In Vivo
Diagnostics Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) 158
Table 79: Latin American Historic Review for Cardiovascular
Disease Diagnostics by Product Segment - In Vitro
Diagnostics and In Vivo Diagnostics Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2000 through 2006 (includes corresponding Graph/Chart) 159
Table 80: Latin American 11-Year Perspective for
Cardiovascular Disease Diagnostics by Product Segment -
Percentage Breakdown of Dollar Sales for In Vitro
Diagnostics and In Vivo Diagnostics Markets for 2000, 2010 &
2015 159
COMPETITIVE LANDSCAPE
Total Companies Profiled: 71 (including Divisions/Subsidiaries - 82)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 57
Canada 3
Japan 4
Europe 15
France 1
Germany 1
The United Kingdom 5
Italy 3
Rest of Europe 5
Asia-Pacific (Excluding Japan) 1
Middle-East 2
------------------------------------------
Global Cardiovascular Disease Diagnostics Industry Page 19/21
20. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Global Cardiovascular Disease Diagnostics Industry
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 4 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Global Cardiovascular Disease Diagnostics Industry Page 20/21
21. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Global Cardiovascular Disease Diagnostics Industry Page 21/21